Inovio Pharmaceuticals Inc Industry and Market Analysis

Inovio Pharmaceuticals Inc is a biotech company that specializes in developing DNA-based immunotherapies for a wide range of diseases.

The company's focus is on creating vaccines and treatments for infectious diseases, cancer, and other conditions.

Inovio's technology, known as electroporation, is a key component of its approach, allowing for the efficient delivery of DNA into cells.

This method has shown promise in early-stage clinical trials, with some studies demonstrating significant immune responses in patients.

Curious to learn more? Check out: Inovio Stock Symbol

Inovio's technology is based on inserting engineered DNA into cells, where it becomes transcribed into mRNA and translated into proteins that elicit an immune response.

This approach has proven to be safe and effective in several clinical trials, including a 2016 dose-escalation Phase I trial for a vaccine against Middle East respiratory syndrome (MERS) coronavirus, where the vaccine candidate, INO-4700, showed only mild symptoms and no adverse effects.

The company's technology can be "targeted" to specific types of cancer and immune diseases, such as those produced by a virus, and has been used to develop vaccines against various viruses, including Zika and COVID-19.

See what others are reading: Trump Media & Technology Group

Inovio's proprietary "Cellectra-3P" technology is a key component of their vaccine development process, and has been used in several studies, including a 2017 trial in Puerto Rico with 160 previously healthy adults.

The company's vaccine candidates, such as INO-4800 and INO-4802, have shown promise in preclinical studies, and are currently undergoing Phase I/II trials.

Inovio has also licensed certain patented technology related to the delivery of gene-based therapeutics into skin, as well as patents involving the delivery of genes or drugs via electroporation, which is a key aspect of their vaccine development process.

Consider reading: Inovio Stock Quote

Inovio Pharmaceuticals has forged partnerships to accelerate the development of its COVID-19 vaccine candidate. The Coalition for Epidemic Preparedness Innovations (CEPI) granted up to $9 million to Inovio in January 2020 to develop a vaccine against SARS-CoV-2.

Inovio has collaborations with the South Korean National Institute of Health and the International Vaccine Institute to develop its COVID-19 vaccine candidate. This partnership aims to leverage global expertise and resources to combat the pandemic.

Inovio is working with Beijing Advaccine Biotechnology Co. to speed up the acceptance of its vaccine by regulatory authorities in China. Plans are underway to begin human clinical trials in China during the first half of 2020.

Inovio has partnerships with manufacturers to scale up production of its vaccine if preliminary efficacy trials are successful. This ensures that the vaccine can be quickly distributed if it proves effective.

Inovio has conducted human Phase I safety studies of its lead vaccine (INO-4800) in the United States and South Korea. The company began these trials in April 2020 to test for immunization against the COVID-19 virus.

Here are some of Inovio's notable partnerships:

Inovio Pharmaceuticals is a biotechnology company that focuses on developing DNA medicines to treat various diseases. Its DNA medicines platform uses precisely designed SynCon technology and CELLECTRA smart devices to deliver DNA plasmids.

The company has a diverse pipeline of products, including VGX-3100 for treating HPV-related cervical high-grade dysplasia, which is currently in Phase 1/2 trial. INO-3107 is another product in the pipeline, also for treating HPV-related recurrent respiratory papillomatosis, and it's under Phase 1/2 trial as well.

Take a look at this: Plains All American Pipeline

Inovio's products also target infectious diseases, such as Ebola Virus Disease, which is being treated with INO-4201 in a Phase 1b trial. The company is also working on a COVID-19 vaccine, INO-4800, which is currently in Phase 3 trial.

Inovio has partnered with several organizations, including the Bill & Melinda Gates Foundation and the U.S. Department of Defense, to develop its products. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio's vaccine candidate, INO-4700, was tested in a 2016 Phase I clinical trial and proved to be safe with only mild symptoms and no adverse effects. The trial also demonstrated immunogenicity, with over 85% of subjects showing immune responses after two vaccinations.

Inovio has also been involved in clinical trials for Zika virus and MERS coronavirus, using its proprietary Cellectra-3P technology. The company announced a preclinical DNA-based vaccine for COVID-19 in February 2020 and began a Phase I trial of the vaccine candidate, INO-4800, in April 2020.

Inovio Pharmaceuticals' financial performance has been under scrutiny. Trailing total returns as of 10/8/2025 are available, which may include dividends or other distributions.

The company's profitability is a concern, with a profit margin of 0.00%. This suggests that Inovio Pharmaceuticals is not generating significant profits from its operations.

Return on Assets (ttm) and Return on Equity (ttm) are both negative, indicating that the company is not generating enough profits to cover its expenses.

Revenue (ttm) is $182.34k, a relatively small amount compared to other companies in the industry. Net Income Available to Common (ttm) is -$87.76M, a significant loss for the company. Diluted EPS (ttm) is -$2.5900, indicating a substantial loss per share.

Here is a summary of the company's 1-year income and revenue:

The fiscal year ends on December 31st, marking the close of a 12-month period of financial activity.

This marks the time when businesses and individuals alike must reconcile their financial statements, ensuring that all transactions are accounted for and reported accurately.

The fiscal year-end process typically involves a thorough review of income statements, balance sheets, and cash flow statements to identify any discrepancies or areas for improvement.

Reconciliations must be completed to ensure that all accounts are up-to-date and reflect the true financial position of the business.

The end of the fiscal year is also a time for tax planning and compliance, as businesses must prepare and submit their tax returns to the relevant authorities.

Businesses can use this opportunity to review their financial performance and make adjustments for the upcoming year.

For another approach, see: Johnson & Johnson - Merck Consumer Pharmaceuticals Company

The 5 Year Return is a crucial metric to understand the long-term performance of an investment. Trailing total returns as of 10/8/2025 for INO include dividends or other distributions.

Benchmarking against the S&P 500 (^GSPC) is a standard practice in the financial industry. The S&P 500 is a widely followed index that represents the market performance of the top 500 publicly traded companies in the US.

In this section, we'll take a closer look at the company's valuation measures.

The market capitalization of the company is $130.73 million.

Enterprise value, a more comprehensive measure of a company's worth, stands at $93.84 million.

The price-to-sales ratio is a staggering 457.36, indicating that the company's stock price is extremely high compared to its revenue.

The price-to-book ratio is 4.58, suggesting that the company's stock price is more than four times its book value.

Here's a summary of the valuation measures:

As we dive into the financial performance of INO, let's take a closer look at some key highlights.

The company's total cash as of the most recent quarter is a respectable $47.55 million.

INO's debt-to-equity ratio is a concerning 37.36%, indicating a significant amount of debt relative to its equity.

The company's levered free cash flow is a negative $45.22 million, suggesting that it's struggling to generate cash from its operations.

INO's revenue for the most recent quarter is a modest $182.34k, but it's down from $217.76K last year, a decrease of 73.83%.

Here's a summary of INO's key financial metrics:

The company's profit margin is a concerning 0.00%, indicating that it's not generating enough revenue to cover its costs.

INO's return on assets is a negative 59.30%, and its return on equity is a negative 140.12%, both of which are alarming signs of financial distress.

Let's keep an eye on these key financial metrics to see if INO can turn its performance around.

Inovio Pharmaceuticals is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol INO.

The company's shares are widely held among institutional and retail investors, with a market capitalization of over $1 billion.

Inovio Pharmaceuticals has a strong track record of attracting investment from top-tier venture capital firms and strategic partners, including Bill Gates' investment firm.

Many analysts recommend buying shares in companies with a strong track record of dividend payments, as seen in the "Dividend History" section. This can provide a relatively stable source of income for investors.

A good example is the company XYZ, which has consistently paid dividends over the past decade, as shown in the "Dividend History" section. This suggests that the company is financially stable and committed to rewarding its shareholders.

Analysts also recommend considering companies with a strong growth potential, as highlighted in the "Market Trends" section. This can be a good way to potentially increase the value of your investment over time.

The "Financial Performance" section shows that company ABC has experienced significant growth in revenue and profits over the past few years, making it an attractive option for investors seeking growth potential.

Some analysts suggest that investors should also consider the company's management team and their track record, as discussed in the "Management Team" section. A strong and experienced management team can be a key factor in a company's success.

The "Risk Factors" section highlights the importance of considering potential risks and challenges when making investment decisions. This can help investors make more informed decisions and avoid potential pitfalls.

For your interest: Paccar Dividend History

The H.C. Wainwright Global Investment Conference is a fantastic opportunity to learn from industry experts and network with fellow investors. This conference is hosted by H.C. Wainwright & Co., a full-service investment bank and asset management firm.

To participate, you can register online through their website, which provides a convenient and easy-to-use platform to sign up. The conference typically takes place in a major city, such as New York or Miami.

During the conference, you can expect to hear from top-notch speakers, including CEOs and other industry leaders, who will share their insights and expertise on various topics. These presentations are a great way to gain valuable knowledge and stay up-to-date on the latest trends and developments.

By participating in the H.C. Wainwright Global Investment Conference, you can expand your professional network and make valuable connections with other investors and industry experts. This can be a game-changer for your investment strategy and future business opportunities.

Recommended read: Goggo Network

The conference also offers a chance to meet one-on-one with company representatives and learn more about their investment opportunities. This is a unique chance to ask questions and get a better understanding of their business models and growth prospects.

You can stay connected with H.C. Wainwright & Co. and receive updates about the conference through their website and social media channels. This will ensure you're always in the loop about upcoming events and important announcements.

Inovio Pharmaceuticals operates in the Health Technology sector and Pharmaceuticals: Major group.

INO's competitors are chosen from within these sectors.

INO's market capitalization is in the micro-capitalization category, with a market cap of $136.58 million. This is up to $300 million.

Here is a brief overview of INO's competitors in the Health Technology sector and Pharmaceuticals: Major group:

We've got some exciting updates to share with you.

The weather forecast for the upcoming week is looking quite gloomy, with a high chance of rain on Tuesday and Wednesday.

The latest data from our weather station indicates that the temperature will be around 15°C on average, with a slight drop in temperature on Wednesday.

Our competitors, AccuWeather and Weather.com, are also predicting rain on Tuesday and Wednesday, but their temperature forecasts are slightly different.

We're keeping a close eye on the situation and will provide further updates as necessary.

Ino Forecasts is a key player in the industry, and its forecasts are worth paying attention to. Ino Forecasts predicted a 25% increase in market share for the upcoming quarter.

One of the most significant factors contributing to this growth is the company's focus on innovation. Ino Forecasts has consistently invested in research and development, resulting in the release of new products and services that cater to the evolving needs of its customers.

The company's ability to adapt to changing market trends has allowed it to stay ahead of its competitors. Ino Forecasts has been able to accurately forecast market shifts and adjust its strategy accordingly.

Ino Forecasts' forecasts are based on a combination of historical data and industry analysis. The company's team of experts carefully reviews market trends and identifies patterns to make informed predictions.

By staying informed about Ino Forecasts' predictions, businesses can make more informed decisions and stay ahead of the competition.

You might enjoy: Logistics in Pharmaceutical Industry

Ino's competitors are included in the Health Technology sector and Pharmaceuticals: Major group. This classification helps us understand their market presence.

Market capitalization is another factor to consider when evaluating Ino's competition. A market cap of $136.58 million places Ino in the micro-capitalization category.

Let's take a look at the competitors' headquarters:

Ino's competitors have a significant presence in the market, with some having thousands of employees. For example, Roche Holding AG has 103,249 employees, while Inovio Pharmaceuticals Inc has 134 employees.

Inovio Pharmaceuticals is a biotech firm that's been working on a COVID-19 vaccine. The company has partnerships with manufacturers to scale up production if preliminary efficacy trials are successful.

Inovio has collaborated with Beijing Advaccine Biotechnology Co. to speed up its acceptance by regulatory authorities in China. They plan to begin human clinical trials in China during the first half of 2020.

Inovio has also partnered with the International Vaccine Institute and Seoul National University, South Korea, to advance human research on INO-4800 in a Phase I-II safety and efficacy trial. The trial will be conducted on 120 participants at Seoul National University Hospital.

Here are some key facts about Inovio's partnerships and trials:

Inovio Pharmaceuticals Inc is collaborating with Beijing Advaccine Biotechnology Co. to speed up its acceptance by regulatory authorities in China, with plans to begin human clinical trials of a candidate vaccine in China during the first half of 2020.

The company has partnerships with manufacturers to scale up production of a vaccine if preliminary efficacy trials are successful. In April 2020, Inovio began human Phase I safety studies of its lead vaccine (INO-4800) in the United States, and a Phase I-II trial in South Korea, to test for immunization against the COVID-19 virus.

Inovio's vaccine, INO-4800, is being tested in multiple countries, including the United States, South Korea, and China. The company is planning to conduct phase III trials outside the United States.

Here are some key facts about Inovio's clinical trials:

Industry analytics play a crucial role in the success of clinical trials. By leveraging data and statistics, sponsors can make informed decisions about trial design, patient recruitment, and resource allocation.

According to a study, the average cost of a clinical trial is around $20 million. This staggering figure highlights the importance of careful planning and budgeting.

Clinical trials often involve complex data collection and analysis. To streamline this process, many companies use electronic data capture (EDC) systems.

In 2020, the global clinical trial management system market was valued at $1.4 billion. This growth is driven by increasing demand for efficient trial management solutions.

Sponsors can use analytics to identify high-risk trials and take proactive measures to mitigate potential issues. By doing so, they can reduce costs and improve trial outcomes.

A well-designed analytics system can also help identify trends and patterns in trial data. This information can inform future trial design and improve overall efficiency.

Worth a look: Dimension Data